A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis-Reference-Cited by-同舟云学术

A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

Published:2006-11-30 Issue:22 Volume:355 Page:2297-2307
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Belfort Renata,Harrison Stephen A.,Brown Kenneth,Darland Celia,Finch Joan,Hardies Jean,Balas Bogdan,Gastaldelli Amalia,Tio Fermin,Pulcini Joseph,Berria Rachele,Ma Jennie Z.,Dwivedi Sunil,Havranek Russell,Fincke Chris,DeFronzo Ralph,Bannayan George A.,Schenker Steven,Cusi Kenneth

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa060326

Cited by 1516 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diabetes as a risk factor for MASH progression;Diabetes Research and Clinical Practice;2024-11

2. Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease;Gut;2024-09-06

3. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD);Journal of Hepatology;2024-09

4. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease;World Journal of Gastroenterology;2024-08-14

5. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07